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Hematological malignancies often express surface HLA class II, making them attractive targets for CD4þ T cell
therapy. We previously demonstrated that HLA class II ligands can be divided into DM-resistant and DM-
sensitive antigens. In contrast to presentation of DM-resistant antigens, presentation of DM-sensitive anti-
gens is suppressed by HLA-DM but can be rescued by HLA-DO. We also showed that HLA-DO expression
remains low in nonhematopoietic cells under inﬂammatory conditions, suggesting that DM-sensitive anti-
gens may be ideal T cell targets with a low risk for graft-versus-host disease. Here, we demonstrated that
B cell malignancies often express HLA-DO and that levels are in particular high in chronic lymphocytic
leukemia. Moreover, we showed that surface presentation of DM-sensitive antigens is regulated by HLA-DO,
and that DM-sensitive antigens are relevant T cell targets for B cell malignancies and, especially, chronic
lymphocytic leukemia. These data open the perspective to target HLA class II ligands with speciﬁc processing
and presentation behavior for CD4þ T cell therapy of hematological malignancies.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic stemcell transplantation (aSCT) in the treatment
of hematological malignancies is the most successful form of
cellular immunotherapy [1]. The beneﬁcial graft-versus-
leukemia (GVL) effect is mediated by donor-derived T cells
recognizing residual leukemic cells of the patient [2]. These
T cells, however, may also react against nonhematopoietic
tissues of the patient, thereby inducing graft-versus-host
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after aSCT [3,4]. A possible approach to shift the balance to-
wards GVL is to exploit CD4þ Tcells, sinceHLA class II is, under
normal conditions,mainly expressed on cells of hematopoietic
origin [5,6]. However, HLA class II can be upregulated on
nonhematopoietic tissues under inﬂammatory conditions.
Recently, we identiﬁed a number of HLA class II restricted
minor histocompatibility antigens [7,8] and analyzed their
processing and presentation behavior. The data showed that
HLA class II ligands can be divided into HLA-DM resistant and
sensitive antigens [9]. DM-resistant antigens are presented on
all HLA class IIpos cells, whereas presentation of DM-sensitive
antigens is decreased by HLA-DM and restored by coex-
pression of its natural inhibitor, HLA-DO. Interestingly, in
contrast to HLA-DM, HLA-DO is hardly upregulated by
proinﬂammatory cytokines [9,10]. We therefore hypothesized
that DM-sensitive antigens are inefﬁciently presented on
nonhematopoietic cells under inﬂammatory conditions. This
makes DM-sensitive antigens attractive targets for CD4þ Tcell
therapieswith a low risk for GVHD. A prerequisite for selective
GVL is, however, that DM-sensitive antigens are presented on
leukemic cells.
Here, we investigated expression of HLA-DM and -DO in
primary leukemic cells, andwe demonstrated that HLA-DO is
often expressed in B cell malignancies, and in particular, in
chronic lymphocytic leukemia (CLL). We further conﬁrmed
the functional relevance of HLA-DO as regulator in surface
presentation of DM-sensitive antigens on leukemic cells.
Our data show that CD4þ T cells directed against DM-
sensitive antigens are promising tools in aSCT and empha-
size the relevance of HLA-DO expression in cell types of
different origins for optimal design of CD4þ T cell based
immunotherapy.
MATERIALS AND METHODS
Cell Samples and Culture
Peripheral blood and bone marrow samples were obtained from pa-
tients and healthy individuals after approval by the Leiden University
Medical Center Institutional Review Board and informed consent according
to the Declaration of Helsinki. Mononuclear cells were isolated by Ficoll-
Isopaque separation. T cells, ﬁbroblasts (FB), dendritic cells, and cell line
LB-ALL-SK were cultured as previously described [9,11].
Microarray Gene Expression Analysis
CD14þmonocytes, CD19þB cells, CD3þTcells, andCD34þhematopoietic
stem cells were isolated from (granulocyte colonyestimulating factoremobi-
lized) peripheral blood fromhealthy donors by ﬂowcytometry. Acutemyeloid
leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leu-
kemia (ALL), chronic lymphocytic leukemia (CLL), andmultiplemyeloma(MM)
were isolated from patient samples by ﬂow cytometry based on expression of
CD33, CD34, CD19, CD19/CD5, and CD38 expression, respectively. FB were
cultured fromskin biopsies in the absence or presence of IFN-g (100 IU/mL) for
4 days. Isolation of total RNA and microarray gene expression analysis was
performed as described recently [9].
Quantitative RT-PCR
Expression of HLA-DOA and HLA-DOB mRNA was measured by quanti-
tative real-time RT-PCR using the Brilliant III Ultra Fast SYBR Green QPCR
Mastermix (Agilent Technologies, Amstelveen, The Netherlands) and the
following primers: DOA: 50- TTTGCCCGCTTTGACCCGCA -30 and 50-
TCACCCGTGGAGGCACGTTG -30 , DOB: 50- AGGAGCAGACAGGCCGTGGA -30 and
50- CCTCTGGTTGCACTTTTCTCCCCA -30 . Gene expression for DOA and DOB
was normalized as a ratio with 18S RNA expression. Ampliﬁcations were
started with 10 minutes at 95C, followed by 50 cycles of 30 seconds for
denaturing at 95C, 30 seconds of annealing at 60C, and 30 seconds exten-
sion at again 60C. After ampliﬁcation, speciﬁcity of the PCR products was
conﬁrmed by melting curve analysis.
Western Blot Analysis
Cells were lysed on ice in 1% triton-X lysis buffer containing protease
inhibitors (Roche Diagnostics, Almere, The Netherlands). The subnuclearfractionwas obtained by centrifugation at 10,000g for 30 minutes. SDS-Page
was run on precast NuPage Novex 10% Bis-Tris Mini gels (Life Technologies,
Bleiswijk, The Netherlands) for 35 minutes at 30 V and blotted on poly-
vinylidene diﬂuoride membrane membranes. HLA-DOB expression was
detected by mouse monoclonal antibody s-69739 (Santa Cruz Biotech-
nology, Dallas, TX) and biotinylated goat antimouse IgG (Life Technologies).
Antigen Presentation Assays
Stimulator cells (3  104 cells/well) and CD4þ T cells (5  103 cells/well)
were overnight coincubated at 37C in 96-well plates. IFN-g release was
measured by ELISA (Sanquin, Amsterdam, The Netherlands). As stimulator
cells, Raji and LB-ALL-SK cell lines and primary CLL and ALL cells were used.
Raji and LB-ALL-SK were retrovirally transduced with HLA-DQA1*01:03/
DQB1*06:03 and HLA-DOA/DOB as recently described [9]. In addition, Raji
and LB-ALL-SK expressing HLA-DQA1*01:03/DQB1*06:03 were transduced
with lentiviral pLKO.1-puro containing short hairpin RNA for HLA-DOA
(TRCN0000057268) or scrambled shRNA (SHC002) from the MISSION li-
brary (Sigma-Aldrich, Zwijndrecht, The Netherlands).
Flow Cytometryebased Cytotoxicity
Target cells (1104 cells/well) and CD4þ Tcells (3104 cells/well) were
overnight coincubated at 37C in 96-well plates. LB-PI4K2B-1S peptide was
added at 1 mg/mL. Cocultures were stained with PE-labeled anti-CD3, and
analyzed by ﬂow cytometry after addition of a ﬁxed number of ﬂow-count
beads and propidium iodide (PI) to allow quantitative measurement of
viable (PI negative) cells. As target cells, FB transduced with HLA-
DQA1*01:03/DQB1*06:03 were used after pretreatment with IFN-g (100
IU/mL) for 4 days.
RESULTS
We recently proposed that DM-sensitive antigens may be
relevant targets for T cells with a selective GVL effect and low
risk for GVHD. To investigate whether DM-sensitive antigens
are relevant targets for GVL, primary leukemic cells of
different origins were collected and compared for expression
of HLA-DM (DMA and DMB) and DO (DOA and DOB) with
nonmalignant hematopoietic cells by microarray gene
expression analysis (Figure 1A). The data showed that pri-
mary leukemic cells (AML, CML, ALL, and CLL) expressed high
levels of HLA-DMA and DMB, except for 2 AML-M3 which
were also low in HLA class II (data not shown). HLA-DMA and
DMB expressionwas low in all HLA class IIneg samples, which
includedMM, T cells, and FB cultured in the absence of IFN-g.
Similar to HLA-DMA and DMB, HLA-DOA expressionwas low
in HLA class IIneg samples, but signiﬁcant expression was
observed in HLA class IIpos AML, CML, ALL, and CLL, except for
7 AML, which included the 2 AML-M3 with low HLA class II.
In contrast to HLA-DMA, DMB and DOA, expression of HLA-
DOB was not or hardly induced in FB by IFN-g, and we pre-
viously demonstrated that DM-sensitive antigens are inefﬁ-
ciently presented on FB in an inﬂammatory environment
because of low levels of induced HLA-DOB [9]. Remarkably, a
strong difference in HLA-DOB expression was observed be-
tween myeloid and lymphatic malignancies, and especially
CLL. Except for mature dendritic cells, all samples from
myeloid origin showed low expression of HLA-DOB, whereas
strong expression was observed in CLL and healthy B cells.
Variable HLA-DOB expression was observed in ALL samples.
HLA-DOB expression was high in the majority of MM, but
these cells were HLA class IIneg (data not shown). The strong
difference in HLA-DOB expression between CLL and myeloid
malignancies could be conﬁrmed by quantitative RT-PCR
(data not shown) and Western blot analysis (Figure 1B).
Strong HLA-DOB protein expression was observed in all CLL,
whereas expression could not be detected in AML
(Figure 1B). ALL cells showed variable HLA-DOB expression
also on protein levels. The slight upregulation of HLA-DOB in
FB cultured under inﬂammatory conditions, which was
observed on mRNA level, did not translate into detectable
Figure 1. HLA-DM and DO expression in primary leukemic cells. (A) The genes encoding the alpha and beta chains of HLA-DM (DMA and DMB) and HLA-DO (DOA
and DOB) were analyzed by microarray gene expression analysis in acute myeloid leukemia (AML; n ¼ 18), chronic myeloid leukemia (CML; n ¼ 6), acute
lymphoblastic leukemia (ALL; n ¼ 9), chronic lymphocytic leukemia (CLL; n ¼ 5) and multiple myeloma (MM; n ¼ 5), as well as in nonmalignant hematopoietic stem
cells (HSC; n ¼ 3), B cells (n ¼ 3), T cells (n ¼ 3), monocytes (n ¼ 3), monocyte-derived immature and mature dendritic cells (imDC and matDC; n ¼ 3), and
nonhematopoietic ﬁbroblasts (FB) cultured in the presence (n ¼ 4) or absence (n ¼ 5) of IFN-g. Normalized probe ﬂuorescence intensities are depicted for individual
samples. Statistical analysis was performed using Student t-tests (n.s.; not signiﬁcant; *P < .01; **P < 1010; ***P < 1020). (B) HLA-DOB protein expression was
measured by Western blot analysis in cell line LB-ALL-SK after retroviral transfer of the HLA-DOB gene, primary FB cultured in the absence or presence of IFN-g,
T cells, B cells, AML, ALL, and CLL. Expression of b-actin is shown as loading control.
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sion, our data show that HLA-DO, in its full heterodimer, is
expressed at high levels in primary CLL and a subgroup of
ALL.
To investigate whether HLA-DO was functionally active in
malignant B cells and regulated surface presentation of DM-
sensitive antigens, we ﬁrst targeted HLA-DO in B cell lym-
phoma cell line Raji and ALL cell line LB-ALL-SK by lentiviral
introduction of HLA-DOA speciﬁc shRNA. Raji and LB-ALL-SK
showed similar expression of HLA-DOA by microarray gene
expression analysis (data not shown), but expression of HLA-
DOB was signiﬁcantly different. HLA-DOB as endogenously
expressed by Raji was clearly detectable on Western blot,
whereas LB-ALL-SK lacked endogenous expression of the
HLA-DOB protein (data not shown). Raji and LB-ALL-SK bothendogenously expressed DM-sensitive antigen LB-PI4K2B-1S
and the HLA-DQB1*06:03 restriction allele was retrovirally
introduced. Quantitative RT-PCR conﬁrmed a decrease in
HLA-DOA mRNA expression upon introduction of speciﬁc,
but not scrambled, shRNA (Supplementary Figure S1A). T cell
experiments demonstrated that upon silencing of HLA-DOA,
presentation of DM-sensitive antigen LB-PI4K2B-1S was
signiﬁcantly diminished, whereas presentation of DM-
resistant control antigens were not affected (Figure 2A).
Next, we enforced HLA-DO expression in LB-ALL-SK by
retroviral introduction of the HLA-DOA and DOB genes.
Overexpression of HLA-DOA and DOB mRNA was conﬁrmed
by quantitative RT-PCR (Supplementary Figure S1B) and
overexpression of HLA-DOB protein was demonstrated by
Western blot analysis (Figure 1B). In T cell experiments,
Figure 2. HLA-DO regulates surface presentation of DM-sensitive antigens on
B cell malignancies. (A) Silencing of HLA-DO by HLA-DOA speciﬁc shRNA re-
duces presentation of DM-sensitive antigen LB-PI4K2B-1S. B cell lymphoma
cell line Raji (upper) and acute lymphoblastic leukemia (ALL) cell line LB-ALL-
SK (lower) both endogenously express DM-sensitive antigen LB-PI4K2B-1S
and the HLA class II restriction allele was expressed after retroviral transfer
of the HLA-DQA1*01:03 and DQB1*06:03 genes. In the next step, Raji and LB-
ALL-SK were transduced with lentiviral vectors containing silencing shRNA for
HLA-DOA (TRCN0000057268) or scrambled control shRNA (SHC002) from the
MISSION library. The T cell clone for LB-PI4K2B-1S is an allo-reactive CD4þ
T cell clone isolated from a patient with CML after HLA-matched alloSCT. For
speciﬁcity of the T cell clone, EBV-LCL from patient and donor were included as
positive and negative controls, respectively. For the Raji cell line, a CD4þ T cell
clone recognizing male-speciﬁc DM-resistant antigen DDX3Y was included as
control, and the HLA class II restriction allele was expressed after retroviral
transfer of the HLA-DQA1*01:01 and DQB1*05:01 genes. For LB-ALL-SK, an
allo-reactive CD4þ T cell clone recognizing an unknown DM-resistant antigen
in the endogenous HLA-DPB1*14:01 molecule was included. Mean release of
IFN-g in duplicate wells of 1 representative experiment is shown, but similar
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gene transfer, whereas presentation of a DM-resistant con-
trol antigen was not altered (Figure 2B).
Finally, we investigated whether high expression of HLA-
DOB in primary CLL as compared with ALL also translated
into strong T cell recognition of DM-sensitive antigens. Pri-
mary CLL and ALL samples were selected for expression of
DM-sensitive antigen LB-PI4K2B-1S and an unknown DM-
resistant antigen recognized by an allo-reactive HLA-
DQB1*06:03especiﬁc T cell or for expression of DM-sensitive
antigen LB-LY75-1K and DM-resistant antigen LB-PTK2B-1T
and their relevant HLA-DR restriction alleles. The data
showed that all leukemic samples were recognized by the
T cells. However, presentation of DM-sensitive antigens was
superior on CLL compared with ALL, whereas presentation of
DM-resistant antigens was comparable (Figure 3A).
Increased expression of HLA-DOA and DOB in these CLL as
compared with ALL samples was conﬁrmed by quantitative
RT-PCR (Supplementary Figure S1C). In conclusion, our data
illustrate that HLA-DO regulates surface presentation of DM-
sensitive antigens on B cell malignancies and that DM-
sensitive antigens are relevant T cell targets, particularly for
primary CLL, which often express high HLA-DO.
Because HLA-DO is not or hardly induced in non-
hematopoietic cells by inﬂammatory cytokines [9,10], DM-
sensitive antigens have been suggested to be T cell targets
with a low risk for GVHD. To test the capacity of non-
hematopoietic cells to present DM-sensitive antigens under
inﬂammatory conditions, we retrovirally introduced HLA-
DQB1*06:03 into skin-derived FB endogenously expressing
LB-PI4K2B-1S and tested T cell mediated lysis of these FB
after pretreatment with IFN-g and overnight coincubation at
an effector to target ratio of 3:1. No or only low speciﬁc lysis
of FB endogenously expressing LB-PI4K2B-1S was measured,
whereas FB exogenously loaded with LB-PI4K2B-1S peptide
showed strong speciﬁc lysis (Figure 3B).
Our data illustrate that DM-sensitive antigens are inefﬁ-
ciently presented on nonhematopoietic cells under inﬂam-
matory conditions, and therefore support the therapeutic
value of DM-sensitive antigens as T cell targets with a low
risk for GVHD.DISCUSSION
We recently demonstrated that DM-sensitive antigens
are inefﬁciently presented on nonhematopoietic cells under
inﬂammatory conditions, suggesting that DM-sensitive an-
tigens may be attractive targets to induce GVL with a re-
duced risk for GVHD. For GVL effect, however, DM-sensitive
antigens should be presented on the surface of leukemic
cells. We here show that HLA-DO is expressed in leukemic
cells and that expression is sufﬁcient for T cell recognition of
DM-sensitive antigens. We demonstrate that HLA-DO
expression is particularly high in primary CLL, and thatresults were obtained in 2 other experiments. Signiﬁcant differences in Stu-
dent t-tests are indicated (*P < .05). (B) Enforced expression of HLA-DO by
retroviral transfer of the HLA-DOB gene enhances presentation of DM-
sensitive antigen LB-PI4K2B-1S. Cell line LB-ALL-SK expressing LB-PI4K2B-1S
and its HLA-DQ restriction allele was retrovirally transduced with HLA-DOB
alone or together with HLA-DOA. T cell recognition of DM-sensitive antigen
LB-PI4K2B-1S and the unknown DM-resistant antigen in HLA-DPB1*14:01 was
measured by IFN-g ELISA. Mean release of IFN-g in duplicate wells of 1
representative experiment is shown, but similar results were obtained in 2
other experiments. Signiﬁcant differences in Student t-tests are indicated
(*P < .05).
Figure 3. DM-sensitive antigens are efﬁciently presented on primary chronic lymphocytic leukemia (CLL) but not on skin-derived ﬁbroblasts (FB) under inﬂam-
matory conditions. (A) DM-sensitive antigens are efﬁciently presented on high HLA-DO expressing CLL cells. Primary acute lymphoblastic leukemia (ALL) and CLL
were selected for expression of LB-PI4K2B-1S and HLA-DQB1*06:03 (left) or expression of LB-LY75-1K and LB-PTK2B-1T and their respective HLA-DRB3*01:01 and
DRB1*13:01 restriction alleles (right). Primary ALL and CLL cells were sorted by ﬂow cytometry and T cell recognition of DM-sensitive antigens LB-PI4K2B-1S and LB-
LY75-1K and DM-resistant antigen LB-PTK2B-1T and an unknown DM-resistant antigen recognized by an allo-reactive HLA-DQB1*06:03-speciﬁc T cell clone was
measured by IFN-g ELISA. Mean release of IFN-g of duplicate wells of 2 independent experiments is depicted. (B) LB-PI4K2B-1S positive FB transduced with HLA-
DQB1*06:03 were tested for lysis by LB-PI4K2B-1S speciﬁc T cells after pretreatment with IFN-g. T cells and FB were coincubated overnight at an effector to
target ratio of 3:1, and numbers of viable (PI negative) FB were measured relative to a ﬁxed number of ﬂow-count beads in a quantitative ﬂow cytometryebased
cytotoxicity assay. T cells for LB-PTK2B-1T were included as negative controls because the FB did not express the HLA-DR restriction allele for these T cells, and HLA-
DQB1*06:03etransduced FB were exogenously loaded with LB-PI4K2B-1S peptide as positive control to conﬁrm the lytic capacity of LB-PI4K2B-1Sespeciﬁc T cells.
Indicated are the side scatter and ﬂuorescence as measured in FL2 for cocultures of T cells and FB. Fluorescence in FL2 for gated FB has been measured as a result of
auto-ﬂuorescence, whereas ﬂuorescence in FL2 for remaining T cells indicates positive staining with PE-labeled anti-CD3 antibody. Numbers of viable (PI negative) FB
after overnight coincubation with the indicated T cells are shown. One representative of 2 experiments is shown.
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recognition of DM-sensitive antigens on CLL as compared
with ALL.
HLA-DM has been described as a chaperone that greatly
accelerates peptide exchange in MHC II [12], and various
studies have shown that HLA-DM induces release of peptides
binding to MHC II with low afﬁnity, resulting in a selection
process that favors presentation of high-afﬁnity peptides
[12-14]. DM-resistant T cell epitopes are, therefore, expected
to bind with higher afﬁnity to HLA class II than DM-sensitiveT cell epitopes. However, because our T cell epitopes are
presented by different HLA class II alleles, each with its own
binding characteristics and kinetics of HLA-DM catalysed
peptide editing [14], an accurate comparison of HLA class II
binding afﬁnity and half-lives between our DM-sensitive and
DM-resistant T cell epitopes is not possible.
Our data show that HLA-DO regulates presentation of
DM-sensitive antigens by HLA class II surface molecules on
leukemic cells. Recently, Guce et al. [15] elucidated the
crystal structure of the DO-DM complex, and demonstrated
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to that proposed for MHC class II and DM. HLA-DO thus acts
as a substrate mimic that tightly binds to DM, thereby pre-
venting access to MHC class II. Guce et al. [15] also demon-
strated that HLA-DO inhibits DM-mediated peptide release
in a dose-dependent manner. Because DM is expressed at
higher levels than DO, free DM and DO-DM complexes are
both present, and the major mechanism for shifting their
balance is via transcription of the DOB subunit [16]. This is
also represented by our data showing constitutive expres-
sion of HLA-DMA, DMB, and DOA in all HLA class II positive
cells, whereas DOB expression is different between lymphoid
and myeloid cells, showing high expression in healthy B cells
and CLL cells and variable expression in ALL. We further
demonstrated that high HLA-DO expression indeed trans-
lates to T cell recognition of DM-sensitive antigens, as (low-
afﬁnity) DM-sensitive peptides are efﬁciently presented on
lymphatic leukemias and especially on CLL. Moreover, HLA-
DOB is not expressed at detectable levels in skin-derived FB
under inﬂammatory conditions, and T cells for DM-sensitive
antigens also failed to lyse cytokine-pretreated FB.
In conclusion, our data demonstrate and conﬁrm the
unique tissue distribution of HLA-DO and its function to
inhibit DM-mediated peptide release in leukemic cells. These
features of HLA-DO may be exploited for development of
novel therapies in which CD4þ T cells for DM-sensitive an-
tigens are used to induce GVL reactivity after aSCT with a low
risk for GVHD.
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